Practice Point® CME Podcasts: Expert Discussions in Oncology™ Titelbild

Practice Point® CME Podcasts: Expert Discussions in Oncology™

Practice Point® CME Podcasts: Expert Discussions in Oncology™

Von: Practice Point Communications
Jetzt kostenlos hören, ohne Abo

Über diesen Titel

Join leading experts in the field of oncology as they explore the latest advancements, trends, and challenges in cancer care. From cutting-edge treatments and clinical trials to the human stories behind the science, each episode delves deep into the evolving landscape of oncology. If you’re seeking AMA, ABS, ANCC, or ACPE credit, these podcasts offer valuable knowledge, expert perspectives, and real-world insights to help you better understand cancer and its impact on individuals and society.

Practice Point Communications 2025
Folgen
  • Episode 14 - Talking TNBC: Advancing Treatment in Triple Negative Breast Cancer: Latest Insights and Clinical Strategies - Part 3

    Episode 14 - Talking TNBC: Advancing Treatment in Triple Negative Breast Cancer: Latest Insights and Clinical Strategies - Part 3
    Jan 19 2025

    Triple-negative breast cancer (TNBC) accounts for 15-20% of all breast cancers. It affects younger women, women of African descent, and those with BRCA1 mutations. TNBC is highly complex, with distinct subtypes that may respond differently to treatments. Recent advancements include immunotherapies, androgen receptor inhibitors, platinum-based drugs, antibody-drug conjugates, PARP inhibitors, and combination therapies. These podcast episodes address educational gaps in TNBC management, offering interactive cases, discussions on emerging treatments, and strategies to improve patient outcomes.

    Launch Date: December 5, 2024

    Release Date: December 5, 2024

    Expiration Date: November 30, 2025

    FACULTY

    Aditya Bardia, MD, MPH, FASCO

    Associate Professor, Medicine, Harvard Medical School

    Attending Physician, Medical Oncology, Massachusetts General Hospital

    Dana-Farber/Harvard Cancer Center, Boston, MA

    Rita Nanda, MD

    Associate Professor of Medicine

    Director, Breast Oncology Program

    The University of Chicago Medicine Chicago, IL

    his podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast.

    https://www.practicepointcme.com/CMEHome/talking-tnbc-advancing-treatment-in-triple-negative-breast-cancer-latest-insights-and-clinical-strategies-19
    Mehr anzeigen Weniger anzeigen
    22 Min.
  • Episode 13- Talking TNBC: Advancing Treatment in Triple Negative Breast Cancer: Latest Insights and Clinical Strategies - Part 2

    Episode 13- Talking TNBC: Advancing Treatment in Triple Negative Breast Cancer: Latest Insights and Clinical Strategies - Part 2
    Jan 19 2025

    Triple-negative breast cancer (TNBC) accounts for 15-20% of all breast cancers. It affects younger women, women of African descent, and those with BRCA1 mutations. TNBC is highly complex, with distinct subtypes that may respond differently to treatments. Recent advancements include immunotherapies, androgen receptor inhibitors, platinum-based drugs, antibody-drug conjugates, PARP inhibitors, and combination therapies. These podcast episodes address educational gaps in TNBC management, offering interactive cases, discussions on emerging treatments, and strategies to improve patient outcomes.

    Launch Date: December 5, 2024

    Release Date: December 5, 2024

    Expiration Date: November 30, 2025

    FACULTY

    Aditya Bardia, MD, MPH, FASCO

    Associate Professor, Medicine, Harvard Medical School

    Attending Physician, Medical Oncology, Massachusetts General Hospital

    Dana-Farber/Harvard Cancer Center, Boston, MA

    Rita Nanda, MD

    Associate Professor of Medicine

    Director, Breast Oncology Program

    The University of Chicago Medicine Chicago, IL

    his podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast.

    https://www.practicepointcme.com/CMEHome/talking-tnbc-advancing-treatment-in-triple-negative-breast-cancer-latest-insights-and-clinical-strategies-19
    Mehr anzeigen Weniger anzeigen
    23 Min.
  • Episode 12 - Talking TNBC: Advancing Treatment in Triple Negative Breast Cancer: Latest Insights and Clinical Strategies - Part 1

    Episode 12 - Talking TNBC: Advancing Treatment in Triple Negative Breast Cancer: Latest Insights and Clinical Strategies - Part 1
    Jan 19 2025

    Triple-negative breast cancer (TNBC) accounts for 15-20% of all breast cancers. It affects younger women, women of African descent, and those with BRCA1 mutations. TNBC is highly complex, with distinct subtypes that may respond differently to treatments. Recent advancements include immunotherapies, androgen receptor inhibitors, platinum-based drugs, antibody-drug conjugates, PARP inhibitors, and combination therapies. These podcast episodes address educational gaps in TNBC management, offering interactive cases, discussions on emerging treatments, and strategies to improve patient outcomes.

    Launch Date: December 5, 2024

    Release Date: December 5, 2024

    Expiration Date: November 30, 2025

    FACULTY

    Aditya Bardia, MD, MPH, FASCO

    Associate Professor, Medicine, Harvard Medical School

    Attending Physician, Medical Oncology, Massachusetts General Hospital

    Dana-Farber/Harvard Cancer Center, Boston, MA

    Rita Nanda, MD

    Associate Professor of Medicine

    Director, Breast Oncology Program

    The University of Chicago Medicine Chicago, IL

    his podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast.

    https://www.practicepointcme.com/CMEHome/talking-tnbc-advancing-treatment-in-triple-negative-breast-cancer-latest-insights-and-clinical-strategies-19
    Mehr anzeigen Weniger anzeigen
    13 Min.
Noch keine Rezensionen vorhanden